Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • 12 Tips for Traveling With Diabetes
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter
Latest
Popular
Top Rated
Diabetes Health Reference Charts
Medications Archives
Print | Email | Share | Comments (0)

Good News For Type 2’s: Amaryl Is Available

Mar 1, 1996

For the majority of Americans who suffer from type 2 diabetes, a new sulfonylurea drug, Amaryl (glimepiride tablets) may be an exciting option. Recently approved by the FDA, is the only drug of its kind indicated for use either on its own or with insulin, although the combined use may increase the potential for hypoglycemia. Amaryl binds to a different insulin receptor site than other sulfonylureas to provide sustained glucose control.

According to Jill Schneider, MD, "Amaryl is indicated as first line therapy to lower blood glucose in people with type 2 diabetes whose blood glucose cannot be controlled by diet or exercise alone."

Doctors will prescribe doses of Amaryl at one to four milligrams daily. According to the manufacturer, Hoechst Marion Roussel, studies have shown that the drug is significantly absorbed from the GI tract within one hour of ingestion. Amaryl performed well in clinical studies among a variety of patients, including obese and hypersensitive subjects. Hoechst Marion Roussel claims Amaryl provides faster glucose stabilization than glipizide and safer stabilization than glyburide.

It is important for people taking Amaryl to follow a regimen of diet and exercise. According to company literature, "Loss of blood glucose control on diet and exercise alone may be transient, thus requiring only short-term administration of Amaryl." Though all sulfonylurea drugs can cause low blood sugar, doctors found Amaryl to be the least likely to cause hypoglycemia.

People who should not take the drug are those with a known hypersensitivity to Amaryl, or those with ketoacidosis.

Amaryl is one of the first products to receive FDA clearance for the newly formed Hoechst Marion Roussel, the global pharmaceutical division of Hoechst AG in Frankfurt, Germany.


Categories: Blood Glucose, Blood Sugar, Diabetes, Insulin, Low Blood Sugar, Medications, Type 2 Issues, Type 2 Medications



You May Also Be Interested In...


Click Here To View Or Post Comments

Comments 0 comments - Mar 1, 1996

©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.